Ipsen is a global biopharmaceutical group dedicated to improving lives and health outcomes through innovative medicines in Oncology, Neuroscience and Rare Disease with a well-established and successful Consumer Healthcare business. We are committed to discovering new treatments in areas with unmet medical needs and improving the quality of life for patients. Ipsen is entering an exciting new era as a leading global biopharmaceutical company committed to delivering innovation for patient care with a goal of launching at least one new molecular entity or meaningful indication each year.
The Milton Park R&D Hub in Oxford hosts about 100 employees within an environment designed to encourage innovation and foster collaboration. It is home to our technological platform for neurotoxins and is a pioneering research and development organization with unique experience in recombinant neurotoxin technology.